Treatment of excessive sleepiness in patients with obstructive sleep apnea: efficacy and safety results of a 6-week, double-blind, placebo-controlled, randomized-withdrawal trial of solriamfetol (JZP-110)

Introduction: Excessive sleepiness (ES), a common symptom of obstructive sleep apnea (OSA), can persist despite primary treatment. Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with wake-promoting effects. This phase 3, 6-week, randomized-withdrawal trial evaluated the efficacy of solriamfetol for treatment of ES in OSA.

Source: Sleep Medicine - December 1, 2017 Category: Sleep Medicine Authors: P.J. Strollo, S. Redline, J. Hedner, N. Collop, D. Chen, J. Li, L.P. Carter, L. Lee, J. Black, J.-L. Pepin Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research